Konstantinopoulos, P. A., Cheng, S., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., Olawaiye, A. B., Winer, I. S., Barroilhet, L. M., Fu, S., McHale, M. T., Schilder, R. J., Färkkilä, A., Chowdhury, D., Curtis, J., Quinn, R. S., Bowes, B., D'Andrea, A. D., Shapiro, G. I., & Matulonis, U. A. (2020). berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet oncology, 21(7), 957–968. http://access.bl.uk/ark:/81055/vdc_100104119877.0x000018